Will biosimilars revolutionize the future of health?

Harriet Lewis, medicines optimization lead for UK trade group the Association of the British Pharmaceutical Industry (ABPI), looks at the impact of biosimilar competition and what comes next, in an Expert View piece.

The ABPI represents UK-based pharma companies researching the newest and most innovative medicines. Our members make both originator biological medicines and make biosimilar medicines so, for want of a better word, we have a foot in both camps.

We work to support the introduction of biosimilars but also work to ensure there is a sustainable and active competitive market. To understand why we talk about biosimilars and the biosimilar market in a unique way, it is important to take a step back.